Peeling Back The Layers: Exploring Axonics Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Axonics (NASDAQ:AXNX) has been rated by 5 analysts in the past three months, with a shift towards a more bullish stance in the last 30 days. The average 12-month price target for AXNX is now $70.0, down from $75.25. Analysts from Truist Securities, Piper Sandler, Morgan Stanley, Needham, and Leerink Partners have adjusted their ratings and price targets. Axonics is a medical technology company with strong financial performance indicators such as a 32.27% revenue growth rate, a 4.22% net margin, and a 0.65% ROE.
December 22, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axonics has received updated analyst ratings and price targets, with a general bullish sentiment and a decrease in the average price target to $70. The company's strong financial performance is likely to support positive investor sentiment.
The recent analyst ratings, with more bullish than bearish stances, and the strong financial performance of Axonics, including significant revenue growth and profitability, are likely to have a positive short-term impact on the stock price. However, the decrease in the average price target may temper some of the potential upside.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100